Immutep Faces Class Action Lawsuit Reminder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Immutep Limited for violations of securities laws, involving securities purchases from March 24, 2025, to March 12, 2026, with a deadline to contact the firm by July 6, 2026, for participation.
- False Statement Allegations: The complaint alleges that Immutep concealed critical results from its TACTI-004 trial, as the company claimed “strong operational progress” in a SEC Form-K filed on January 30, 2026, despite knowing the trial would not meet its primary efficacy endpoints, leading to investor losses.
- Legal Representation Information: The Schall Law Firm offers free consultations and encourages affected investors to contact Brian Schall to understand their rights and participate in the lawsuit, highlighting the firm's specialization in securities class actions and shareholder rights litigation.
- Lawsuit Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who take no action will be considered absent class members, underscoring the importance of participating in the lawsuit.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMMP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMMP
Wall Street analysts forecast IMMP stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.389
Low
12.00
Averages
12.00
High
12.00
Current: 0.389
Low
12.00
Averages
12.00
High
12.00
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immutep Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Immutep Limited for violations of securities laws, involving securities purchases from March 24, 2025, to March 12, 2026, with a deadline to contact the firm by July 6, 2026, for participation.
- False Statement Allegations: The complaint alleges that Immutep concealed critical results from its TACTI-004 trial, as the company claimed “strong operational progress” in a SEC Form-K filed on January 30, 2026, despite knowing the trial would not meet its primary efficacy endpoints, leading to investor losses.
- Legal Representation Information: The Schall Law Firm offers free consultations and encourages affected investors to contact Brian Schall to understand their rights and participate in the lawsuit, highlighting the firm's specialization in securities class actions and shareholder rights litigation.
- Lawsuit Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who take no action will be considered absent class members, underscoring the importance of participating in the lawsuit.
See More
IMMP Stock Plummets 83% Following Trial Discontinuation
- Stock Collapse: Immutep's shares plummeted 83% on March 13, 2026, after the company disclosed the discontinuation of its TACTI-004 Phase III trial for futility, with the stock price dropping from $2.76 to $0.48, resulting in significant losses for investors.
- False Trial Progress Claims: Between March 24, 2025, and March 12, 2026, Immutep repeatedly claimed that the TACTI-004 trial was progressing well, while internal data indicated a high risk of failure, leading to a decline in investor trust and confidence in the company.
- Legal Action Initiated: Affected investors are encouraged to contact SueWallSt for potential compensation, with a deadline of July 6, 2026, highlighting serious concerns about the company's disclosure practices and their impact on market fairness.
- Investor Rights Protection: Investors who sold their IMMP shares during the class period can still participate in the lawsuit, emphasizing the legal system's commitment to protecting investor rights and ensuring accountability for corporate misrepresentation.
See More
Immutep Faces Class Action Lawsuit Impacting Stock Price Dramatically
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Immutep, alleging securities fraud and other unlawful business practices, with investors advised to apply as Lead Plaintiff by July 6, 2026, indicating significant legal risks that could tarnish the company's reputation.
- Trial Discontinuation: On March 13, 2026, Immutep disclosed that the Independent Data Monitoring Committee recommended halting the TACTI-004 Phase III trial, which evaluates eftilagimod alfa in non-small cell lung cancer patients, potentially hindering the company's R&D progress in a competitive market.
- Stock Price Plunge: Following this news, Immutep's American Depositary Receipt (ADR) price plummeted by $2.27, or 82.44%, closing at $0.48 on March 13, 2026, reflecting extreme pessimism in the market regarding the company's future prospects.
- Legal Firm Background: Pomerantz LLP, a leading firm in securities class litigation with over 85 years of experience, focuses on advocating for victims of securities fraud, and this lawsuit may attract further investor scrutiny, exacerbating the legal and financial pressures faced by Immutep.
See More
Immutep Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Immutep, seeking damages for investors who purchased the company's securities between March 24, 2025, and March 12, 2026, reflecting strong investor response to potential fraud allegations.
- False Statements Allegations: The complaint alleges that Immutep and its executives made materially false and misleading statements during the class period, failing to disclose the true status of the TACTI-004 trial, which could mislead investors about the company's prospects and impact stock prices and market confidence.
- Legal Consequences and Deadline: Investors must apply to be lead plaintiffs by July 6, 2026, to participate in potential recovery, indicating the urgency of legal proceedings and the protection of investor rights.
- Law Firm Background: Bronstein, Gewirtz & Grossman LLC is recognized for recovering hundreds of millions for investors, emphasizing their expertise and experience in securities fraud class actions, which may enhance investor confidence in the case.
See More
Immutep ADRs Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, to apply as lead plaintiffs by July 6, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Immutep concealed critical clinical data regarding the TACTI-004 trial, leading to investor losses when the truth emerged, particularly after the company claimed strong trial progress while risks of failure existed.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first for the number of securities class action settlements in 2017, highlighting its expertise and influence in the field.
- Investor Guidance: Investors are advised to select counsel with proven success in securities litigation, avoiding firms that merely act as intermediaries, to ensure effective legal representation and support in the class action process.
See More
Immutep Faces Class Action Lawsuit, Shares Plunge 82.44%
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Immutep, alleging securities fraud by the company and certain officers, with investors advised to apply as Lead Plaintiff by July 6, 2026, highlighting serious governance concerns.
- Trial Discontinuation: On March 13, 2026, Immutep announced the Independent Data Monitoring Committee's recommendation to halt the TACTI-004 Phase III trial, resulting in an 82.44% drop in share price, reflecting investor pessimism about the company's future prospects.
- Stock Price Volatility: Following the trial discontinuation announcement, Immutep's American Depositary Receipt (ADR) fell by $2.27 to close at $0.48, indicating a significant loss of market confidence in its product development capabilities, which may hinder future financing efforts.
- Potential Legal Consequences: The class action lawsuit could expose Immutep to substantial damages, exacerbating its financial strain while potentially damaging its reputation and investor confidence in the biopharmaceutical sector.
See More
Immutep Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Immutep Limited for violations of securities laws, involving securities purchases from March 24, 2025, to March 12, 2026, with a deadline to contact the firm by July 6, 2026, for participation.
- False Statement Allegations: The complaint alleges that Immutep concealed critical results from its TACTI-004 trial, as the company claimed “strong operational progress” in a SEC Form-K filed on January 30, 2026, despite knowing the trial would not meet its primary efficacy endpoints, leading to investor losses.
- Legal Representation Information: The Schall Law Firm offers free consultations and encourages affected investors to contact Brian Schall to understand their rights and participate in the lawsuit, highlighting the firm's specialization in securities class actions and shareholder rights litigation.
- Lawsuit Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who take no action will be considered absent class members, underscoring the importance of participating in the lawsuit.
See More
IMMP Stock Plummets 83% Following Trial Discontinuation
- Stock Collapse: Immutep's shares plummeted 83% on March 13, 2026, after the company disclosed the discontinuation of its TACTI-004 Phase III trial for futility, with the stock price dropping from $2.76 to $0.48, resulting in significant losses for investors.
- False Trial Progress Claims: Between March 24, 2025, and March 12, 2026, Immutep repeatedly claimed that the TACTI-004 trial was progressing well, while internal data indicated a high risk of failure, leading to a decline in investor trust and confidence in the company.
- Legal Action Initiated: Affected investors are encouraged to contact SueWallSt for potential compensation, with a deadline of July 6, 2026, highlighting serious concerns about the company's disclosure practices and their impact on market fairness.
- Investor Rights Protection: Investors who sold their IMMP shares during the class period can still participate in the lawsuit, emphasizing the legal system's commitment to protecting investor rights and ensuring accountability for corporate misrepresentation.
See More
Immutep Faces Class Action Lawsuit Impacting Stock Price Dramatically
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Immutep, alleging securities fraud and other unlawful business practices, with investors advised to apply as Lead Plaintiff by July 6, 2026, indicating significant legal risks that could tarnish the company's reputation.
- Trial Discontinuation: On March 13, 2026, Immutep disclosed that the Independent Data Monitoring Committee recommended halting the TACTI-004 Phase III trial, which evaluates eftilagimod alfa in non-small cell lung cancer patients, potentially hindering the company's R&D progress in a competitive market.
- Stock Price Plunge: Following this news, Immutep's American Depositary Receipt (ADR) price plummeted by $2.27, or 82.44%, closing at $0.48 on March 13, 2026, reflecting extreme pessimism in the market regarding the company's future prospects.
- Legal Firm Background: Pomerantz LLP, a leading firm in securities class litigation with over 85 years of experience, focuses on advocating for victims of securities fraud, and this lawsuit may attract further investor scrutiny, exacerbating the legal and financial pressures faced by Immutep.
See More
Immutep Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Immutep, seeking damages for investors who purchased the company's securities between March 24, 2025, and March 12, 2026, reflecting strong investor response to potential fraud allegations.
- False Statements Allegations: The complaint alleges that Immutep and its executives made materially false and misleading statements during the class period, failing to disclose the true status of the TACTI-004 trial, which could mislead investors about the company's prospects and impact stock prices and market confidence.
- Legal Consequences and Deadline: Investors must apply to be lead plaintiffs by July 6, 2026, to participate in potential recovery, indicating the urgency of legal proceedings and the protection of investor rights.
- Law Firm Background: Bronstein, Gewirtz & Grossman LLC is recognized for recovering hundreds of millions for investors, emphasizing their expertise and experience in securities fraud class actions, which may enhance investor confidence in the case.
See More
Immutep ADRs Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, to apply as lead plaintiffs by July 6, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Immutep concealed critical clinical data regarding the TACTI-004 trial, leading to investor losses when the truth emerged, particularly after the company claimed strong trial progress while risks of failure existed.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first for the number of securities class action settlements in 2017, highlighting its expertise and influence in the field.
- Investor Guidance: Investors are advised to select counsel with proven success in securities litigation, avoiding firms that merely act as intermediaries, to ensure effective legal representation and support in the class action process.
See More
Immutep Faces Class Action Lawsuit, Shares Plunge 82.44%
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Immutep, alleging securities fraud by the company and certain officers, with investors advised to apply as Lead Plaintiff by July 6, 2026, highlighting serious governance concerns.
- Trial Discontinuation: On March 13, 2026, Immutep announced the Independent Data Monitoring Committee's recommendation to halt the TACTI-004 Phase III trial, resulting in an 82.44% drop in share price, reflecting investor pessimism about the company's future prospects.
- Stock Price Volatility: Following the trial discontinuation announcement, Immutep's American Depositary Receipt (ADR) fell by $2.27 to close at $0.48, indicating a significant loss of market confidence in its product development capabilities, which may hinder future financing efforts.
- Potential Legal Consequences: The class action lawsuit could expose Immutep to substantial damages, exacerbating its financial strain while potentially damaging its reputation and investor confidence in the biopharmaceutical sector.
See More
